Chlamydia pneumoniae plays a critical role in coronary artery disease, in order to justify antibiotic therapy.
Response
We appreciate Gurfinkel et al's interest in our 6-month report of the ACADEMIC study, 1 which found significantly reduced (Pϭ0.011, Pϭ0.027) global indexes of inflammation in coronary artery disease (CAD) patients given azithromycin versus those given placebo. 1 ACADEMIC was designed to have high power to evaluate inflammatory markers. Its primary clinical end point at 2 years has not yet been reported, but its 7248 patient-months of follow-up will constitute the largest database of the 3 reported studies (202 2 and 1080 3 patient-months, respectively).
We agree with Gurfinkel et al that ROXIS 2 studied a different (unstable) stage of CAD; we 1 excluded unstable angina or acute myocardial infarction (MI). The British study 3 enrolled stable patients an average of 43 months after MI. Similarly, most of our patients (60%) had a history of MI; the others had undergone bypass surgery or coronary intervention.
Our 2-year clinical event rates will be of interest, but both we 1 and Grayston 4 emphasize the need for larger, longer-term studies, well-powered to detect worthwhile event reductions of 20% to 30%. Our 6-month events number too few to exclude an important treatment effect and should be viewed as exploratory.
We also were surprised to find that differences between groups in inflammatory markers did not develop until after 3 months. This was due to transient falls in marker values in the placebo (as well as active) group at 3 months. We can only speculate as to the cause; it may relate to better general care (eg, aspirin use, treatment of infections and lipids) during the 3-month treatment phase. If differences in inflammatory markers precede reductions in clinical events, then treatment for Ͼ3 months, as proposed for ACES (Azithromycin and Coronary Events Study), 4 may be required.
We stress the importance of ROXIS, 2 which tested antibiotics for unstable coronary syndromes. We should have better characterized ROXIS as enrolling patients whose seropositivity (rather than clinical characteristics) was unrestricted. As we discussed, 1 the inclusion of seronegative patients 2 will help to determine whether treatment effects are specifically antichlamydial.
We agree that Chlamydia pneumoniae seropositivity is an imperfect marker of persistent infection; it may be associated with substantial false-positive and -negative rates. However, the high rate (79% 5 ) of coronary antigen positivity in our patients suggests a high prevalence of persistent chlamydial arteritis.
Our findings should stimulate further research on the infection-inflammation hypothesis of atherosclerosis, including larger and longer-term trials. 1, 4 Previous reports of dramatic benefit, based on limited experience, may have been overly enthusiastic.
Enrique Gurfinkel, Gerardo Bozovich and Branco Mautner in Coronary Artery Disease Chlamydia pneumoniae
